Metacrine, Inc. (MTCR)
Metacrine, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $0.58, down 1.29% on the session, giving a market capitalisation of $0. On trailing twelve-month figures it carries a trailing P/E of -0.40, a net margin of 0.0%. Its beta of -0.74 implies it has historically moved less than the broad market.
Metacrine, Inc., established in 2014 and operating from its headquarters in San Diego, California, is a clinical-stage biopharmaceutical company. The firm's core mission involves identifying and advancing novel therapies specifically designed for patients suffering from gastrointestinal disorders. Among its developmental pipeline, Metacrine is progressing MET642, a therapeutic candidate which has successfully completed its Phase I clinical investigation aimed at treating ulcerative colitis.
Metacrine, Inc. is most often compared with the following Healthcare names: